Author Archives: Marylyn Donahue

High Price of Gilead's Sovaldi Could Deter Early Hep C Treatment

Gilead Silences has cleaned up on their new $1,000 Hepatitis C pill Sovaldi (84,000 per treatment), hauling in a record-breaking $2.3 billion in its first full quarter on the market. The previous record (also a Hepatitis C drug Incivek from Vertex) came in with $1.56 billion, according to EP Vantage. And Sovaldi may well go […]
Posted in healthcare, pricing | Tagged , , | Leave a comment

Is Gilead’s $1000 Pill Worth It?

The Department of Veterans Affairs and other California panels’ solution to the new and extremely costly hepatitis (Hep) C drugs (Sovaldi and Olysio) is to reserve them for the patients with advanced liver diseases, including those awaiting transplants. What should the patients of “milder” cases do then? Twiddle their thumbs and wait for drugs in […]
Posted in pricing, Regulatory | Tagged , , , , | 2 Comments

The Fort Hood Killing and Psychotropic Drugs

In response to the recent shooting at Fort Hood that killed four (including the killer’s suicide) and wounded 16, the mental health watchdog Citizens Commission on Human Rights (CCHR) views this and other recent incidents as a wake-up call to the dangers of antidepressants, anti-psychotics and anti-anxiety drugs, which between them have accumulated 22 international drug […]
Posted in Safety | Tagged , , , | Leave a comment

The Rise of the Patient Participant

Either the doctor’s best friend or nightmare, the e-patient movement (the ‘e’ could stand for engaged or empowered) is here to stay and growing, writes Marylyn Donahue. Championing patients as full partners in their own medical care, via the use of online communities and social media sites are slowly but surely turning patients into participants […]
Posted in E-Media, healthcare, Medical Education, multimedia, Patient Communication, patient education, social media, Technology | Tagged , , , | Leave a comment

“The Secret of Successful Drug Launches”

We love being told secrets especially about something so few know anything about, like how to launch a drug successfully given two-thirds don’t meet expectations. And those new drugs once launched fail to meet prelaunch consensus sales expectations for their first year on the market, and those that fall short typically continue to under-deliver for […]
Posted in Marketing, Strategy | Tagged , , | 1 Comment
  • Categories

  • Meta